|
Arcutis Bioterapeutics, Inc. (ARQT) Valoración de DCF
US | Healthcare | Biotechnology | NASDAQ
|
- ✓ Completamente Editable: Adáptelo A Sus Necesidades En Excel O Sheets
- ✓ Diseño Profesional: Plantillas Confiables Y Estándares De La Industria
- ✓ Predeterminadas Para Un Uso Rápido Y Eficiente
- ✓ No Se Necesita Experiencia; Fáciles De Seguir
Arcutis Biotherapeutics, Inc. (ARQT) Bundle
Ya sea que sea un inversor o analista, esta calculadora DCF (ARQT) es su herramienta esencial para una valoración precisa. Prelabastado con los datos reales de Arcutis BioTherapeutics, Inc., puede ajustar los pronósticos y observar los efectos en tiempo real.
Discounted Cash Flow (DCF) - (USD MM)
| Year | AY1 2019 |
AY2 2020 |
AY3 2021 |
AY4 2022 |
AY5 2023 |
FY1 2024 |
FY2 2025 |
FY3 2026 |
FY4 2027 |
FY5 2028 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | .0 | .0 | .0 | 3.7 | 59.6 | 74.5 | 93.1 | 116.4 | 145.5 | 181.9 |
| Revenue Growth, % | 0 | 0 | 0 | 0 | 1517.09 | 25 | 25 | 25 | 25 | 25 |
| EBITDA | -41.8 | -135.2 | -205.6 | -294.6 | -227.4 | 14.9 | 18.6 | 23.3 | 29.1 | 36.4 |
| EBITDA, % | 100 | 100 | 100 | -7991.13 | -381.56 | 20 | 20 | 20 | 20 | 20 |
| Depreciation | .2 | .5 | .8 | 1.3 | 1.9 | 50.2 | 62.8 | 78.5 | 98.1 | 122.7 |
| Depreciation, % | 100 | 100 | 100 | 33.99 | 3.16 | 67.43 | 67.43 | 67.43 | 67.43 | 67.43 |
| EBIT | -42.0 | -135.7 | -206.4 | -295.8 | -229.3 | 14.9 | 18.6 | 23.3 | 29.1 | 36.4 |
| EBIT, % | 100 | 100 | 100 | -8025.12 | -384.72 | 20 | 20 | 20 | 20 | 20 |
| Total Cash | 101.3 | 284.4 | 387.1 | 409.6 | 271.9 | 74.5 | 93.1 | 116.4 | 145.5 | 181.9 |
| Total Cash, percent | .0 | .0 | .0 | .0 | .0 | .0 | .0 | .0 | .0 | .0 |
| Account Receivables | .0 | .5 | .0 | 8.5 | 25.8 | 66.1 | 82.6 | 103.2 | 129.0 | 161.3 |
| Account Receivables, % | 100 | 100 | 100 | 229.46 | 43.3 | 88.66 | 88.66 | 88.66 | 88.66 | 88.66 |
| Inventories | .0 | -.5 | 1.2 | 7.5 | 13.1 | 62.9 | 78.6 | 98.3 | 122.8 | 153.5 |
| Inventories, % | 100 | 100 | 100 | 203.85 | 22.03 | 84.41 | 84.41 | 84.41 | 84.41 | 84.41 |
| Accounts Payable | 1.4 | 7.1 | 7.4 | 8.8 | 12.0 | 62.6 | 78.3 | 97.8 | 122.3 | 152.8 |
| Accounts Payable, % | 100 | 100 | 100 | 239.47 | 20.12 | 84.02 | 84.02 | 84.02 | 84.02 | 84.02 |
| Capital Expenditure | -.3 | -.3 | -1.0 | -23.3 | -.4 | -15.0 | -18.8 | -23.5 | -29.3 | -36.6 |
| Capital Expenditure, % | 100 | 100 | 100 | -631.66 | -0.71805 | -20.14 | -20.14 | -20.14 | -20.14 | -20.14 |
| Tax Rate, % | -1.2 | -1.2 | -1.2 | -1.2 | -1.2 | -1.2 | -1.2 | -1.2 | -1.2 | -1.2 |
| EBITAT | -42.0 | -135.7 | -205.9 | -305.1 | -232.1 | 14.9 | 18.6 | 23.3 | 29.1 | 36.4 |
| Depreciation | ||||||||||
| Changes in Account Receivables | ||||||||||
| Changes in Inventories | ||||||||||
| Changes in Accounts Payable | ||||||||||
| Capital Expenditure | ||||||||||
| UFCF | -40.7 | -129.8 | -207.1 | -340.5 | -250.4 | 10.7 | 46.1 | 57.6 | 72.0 | 90.0 |
| WACC, % | 10.8 | 10.8 | 10.79 | 10.8 | 10.8 | 10.8 | 10.8 | 10.8 | 10.8 | 10.8 |
| PV UFCF | ||||||||||
| SUM PV UFCF | 191.2 | |||||||||
| Long Term Growth Rate, % | 2.00 | |||||||||
| Free cash flow (T + 1) | 92 | |||||||||
| Terminal Value | 1,043 | |||||||||
| Present Terminal Value | 625 | |||||||||
| Enterprise Value | 816 | |||||||||
| Net Debt | 118 | |||||||||
| Equity Value | 699 | |||||||||
| Diluted Shares Outstanding, MM | 69 | |||||||||
| Equity Value Per Share | 10.08 |
What You Will Get
- Real ARQT Financial Data: Pre-filled with Arcutis Biotherapeutics’ historical and projected data for precise analysis.
- Fully Editable Template: Modify key inputs like revenue growth, WACC, and EBITDA % with ease.
- Automatic Calculations: See Arcutis Biotherapeutics’ intrinsic value update instantly based on your changes.
- Professional Valuation Tool: Designed for investors, analysts, and consultants seeking accurate DCF results.
- User-Friendly Design: Simple structure and clear instructions for all experience levels.
Key Features
- Real-Life ARQT Data: Pre-filled with Arcutis Biotherapeutics' historical financials and forward-looking projections.
- Fully Customizable Inputs: Adjust revenue growth, margins, WACC, tax rates, and capital expenditures.
- Dynamic Valuation Model: Automatic updates to Net Present Value (NPV) and intrinsic value based on your inputs.
- Scenario Testing: Create multiple forecast scenarios to analyze different valuation outcomes.
- User-Friendly Design: Simple, structured, and designed for professionals and beginners alike.
How It Works
- Download the Template: Gain immediate access to the Excel-based ARQT DCF Calculator.
- Input Your Assumptions: Modify the yellow-highlighted cells for growth rates, WACC, margins, and other variables.
- Instant Calculations: The model automatically recalculates Arcutis Biotherapeutics' intrinsic value.
- Test Scenarios: Experiment with different assumptions to assess potential changes in valuation.
- Analyze and Decide: Utilize the results to inform your investment or financial analysis.
Why Choose This Calculator for Arcutis Biotherapeutics, Inc. (ARQT)?
- Designed for Experts: An advanced tool utilized by researchers, financial analysts, and industry professionals.
- Accurate Data: Arcutis’ historical and forecasted financial information preloaded for precision.
- Flexible Scenario Analysis: Effortlessly test various projections and assumptions.
- Insightful Outputs: Automatically computes intrinsic value, NPV, and essential financial metrics.
- User-Friendly: Comprehensive instructions lead you through each step of the calculation.
Who Should Use This Product?
- Healthcare Professionals: Understand innovative dermatological treatments and their market potential.
- Researchers: Utilize advanced models to study the efficacy of Arcutis' therapies in clinical settings.
- Investors: Evaluate your investment strategies and analyze the market performance of Arcutis Biotherapeutics (ARQT).
- Pharmaceutical Analysts: Enhance your analysis with a customizable model tailored to biopharmaceutical valuations.
- Entrepreneurs: Discover how biopharmaceutical companies like Arcutis are assessed in the industry.
What the Template Contains
- Preloaded ARQT Data: Historical and projected financial data, including revenue, EBIT, and capital expenditures.
- DCF and WACC Models: Professional-grade sheets for calculating intrinsic value and Weighted Average Cost of Capital.
- Editable Inputs: Yellow-highlighted cells for adjusting revenue growth, tax rates, and discount rates.
- Financial Statements: Comprehensive annual and quarterly financials for deeper analysis.
- Key Ratios: Profitability, leverage, and efficiency ratios to evaluate performance.
- Dashboard and Charts: Visual summaries of valuation outcomes and assumptions.